image
Healthcare - Medical - Devices - NYSE - US
$ 67.76
2.42 %
$ 40 B
Market Cap
26.16
P/E
1. INTRINSIC VALUE

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.[ Read More ]

The intrinsic value of one EW stock under the base case scenario is HIDDEN Compared to the current market price of 67.8 USD, Edwards Lifesciences Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EW

image
FINANCIALS
6 B REVENUE
11.56%
1.53 B OPERATING INCOME
-12.26%
1.4 B NET INCOME
-8.05%
896 M OPERATING CASH FLOW
-26.47%
174 M INVESTING CASH FLOW
-31.11%
-711 M FINANCING CASH FLOW
55.13%
1.35 B REVENUE
-2.27%
394 M OPERATING INCOME
8.12%
3.07 B NET INCOME
734.02%
352 M OPERATING CASH FLOW
-5.30%
2.7 B INVESTING CASH FLOW
2064.82%
-977 M FINANCING CASH FLOW
-911.08%
Balance Sheet Decomposition Edwards Lifesciences Corporation
image
Current Assets 4.04 B
Cash & Short-Term Investments 1.64 B
Receivables 837 M
Other Current Assets 1.55 B
Non-Current Assets 5.33 B
Long-Term Investments 584 M
PP&E 1.84 B
Other Non-Current Assets 2.9 B
Current Liabilities 1.2 B
Accounts Payable 201 M
Short-Term Debt 49.8 M
Other Current Liabilities 944 M
Non-Current Liabilities 1.45 B
Long-Term Debt 670 M
Other Non-Current Liabilities 778 M
EFFICIENCY
Earnings Waterfall Edwards Lifesciences Corporation
image
Revenue 6 B
Cost Of Revenue 1.38 B
Gross Profit 4.62 B
Operating Expenses 3.09 B
Operating Income 1.53 B
Other Expenses 135 M
Net Income 1.4 B
RATIOS
77.02% GROSS MARGIN
77.02%
25.55% OPERATING MARGIN
25.55%
23.35% NET MARGIN
23.35%
21.09% ROE
21.09%
14.98% ROA
14.98%
18.47% ROIC
18.47%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Edwards Lifesciences Corporation
image
Net Income 1.4 B
Depreciation & Amortization 145 M
Capital Expenditures -266 M
Stock-Based Compensation 139 M
Change in Working Capital -526 M
Others -232 M
Free Cash Flow 630 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Edwards Lifesciences Corporation
image
Wall Street analysts predict an average 1-year price target for EW of $83.4 , with forecasts ranging from a low of $66 to a high of $110 .
EW Lowest Price Target Wall Street Target
66 USD -2.60%
EW Average Price Target Wall Street Target
83.4 USD 23.11%
EW Highest Price Target Wall Street Target
110 USD 62.34%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Edwards Lifesciences Corporation
image
Sold
0-3 MONTHS
2.74 M USD 3
3-6 MONTHS
3.09 M USD 4
6-9 MONTHS
22.7 M USD 8
9-12 MONTHS
14 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
49.8 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
4 days ago
Nov 13, 2024
Sell 328 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
65.5686 USD
1 week ago
Nov 05, 2024
Sell 1.65 M USD
Wood Larry L
Global President TAVR & Surg
- 25000
65.9145 USD
1 month ago
Oct 15, 2024
Sell 348 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
69.5067 USD
2 months ago
Sep 11, 2024
Sell 334 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
66.7651 USD
2 months ago
Aug 20, 2024
Sell 87.4 K USD
Chopra Daveen
CVP, TMTT
- 1250
69.9501 USD
3 months ago
Aug 14, 2024
Sell 330 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
66.084 USD
4 months ago
Jul 11, 2024
Sell 47.1 K USD
Lippis Daniel J.
CVP, JAPAC
- 500
94.18 USD
4 months ago
Jul 10, 2024
Sell 466 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
93.2948 USD
4 months ago
Jun 20, 2024
Sell 48.2 K USD
Lippis Daniel J.
CVP, JAPAC
- 535
90 USD
4 months ago
Jun 20, 2024
Sell 35.2 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 400
88.1125 USD
4 months ago
Jun 20, 2024
Sell 457 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 5225
87.4666 USD
5 months ago
Jun 12, 2024
Sell 438 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
87.5393 USD
5 months ago
May 30, 2024
Sell 756 K USD
Zovighian Bernard J
CEO
- 8617
87.68 USD
5 months ago
May 21, 2024
Sell 509 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 5625
90.4539 USD
6 months ago
May 10, 2024
Sell 439 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5000
87.8076 USD
6 months ago
May 07, 2024
Sell 73.4 K USD
Lippis Daniel J.
CVP, JAPAC
- 857
85.6 USD
6 months ago
May 06, 2024
Bought 49.8 K USD
Zovighian Bernard J
CEO
+ 580.2601
85.7421 USD
6 months ago
May 02, 2024
Sell 1.04 M USD
MUSSALLEM MICHAEL A
Director
- 12207
85.02 USD
6 months ago
May 02, 2024
Sell 1.45 M USD
MUSSALLEM MICHAEL A
Director
- 17143
84.59 USD
6 months ago
May 01, 2024
Sell 183 K USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 2160
84.8325 USD
6 months ago
May 01, 2024
Sell 1.03 M USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 12240
84.1053 USD
6 months ago
Apr 30, 2024
Sell 60.5 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 700
86.4036 USD
6 months ago
Apr 30, 2024
Sell 562 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 6550
85.7373 USD
7 months ago
Apr 09, 2024
Sell 79.1 K USD
Lippis Daniel J.
CVP, JAPAC
- 857
92.34 USD
7 months ago
Apr 08, 2024
Sell 9.91 K USD
Lemercier Jean-Luc M
CVP, EMEACLA
- 107
92.65 USD
7 months ago
Apr 08, 2024
Sell 1.32 M USD
Lemercier Jean-Luc M
CVP, EMEACLA
- 14293
92.322 USD
7 months ago
Apr 08, 2024
Sell 9.27 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 100
92.66 USD
7 months ago
Apr 08, 2024
Sell 1.14 M USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 12400
92.3287 USD
7 months ago
Apr 04, 2024
Sell 18.8 K USD
MUSSALLEM MICHAEL A
Director
- 200
94.19 USD
7 months ago
Apr 04, 2024
Sell 254 K USD
MUSSALLEM MICHAEL A
Director
- 2712
93.72 USD
7 months ago
Apr 04, 2024
Sell 899 K USD
MUSSALLEM MICHAEL A
Director
- 9820
91.54 USD
7 months ago
Apr 04, 2024
Sell 1.54 M USD
MUSSALLEM MICHAEL A
Director
- 16618
92.7 USD
7 months ago
Apr 01, 2024
Sell 82.9 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 868
95.51 USD
7 months ago
Apr 01, 2024
Sell 606 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 6387
94.8052 USD
8 months ago
Mar 13, 2024
Sell 1.32 M USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 14500
91.0135 USD
8 months ago
Mar 11, 2024
Sell 1.32 M USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 14400
91.677 USD
8 months ago
Mar 07, 2024
Sell 156 K USD
Lippis Daniel J.
CVP, JAPAC
- 1715
90.98 USD
8 months ago
Mar 04, 2024
Sell 1.15 M USD
MUSSALLEM MICHAEL A
Director
- 13310
86.21 USD
8 months ago
Mar 04, 2024
Sell 1.4 M USD
MUSSALLEM MICHAEL A
Director
- 16040
87.05 USD
8 months ago
Feb 29, 2024
Sell 621 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
85.5855 USD
8 months ago
Feb 23, 2024
Sell 268 K USD
GALLAHUE KIERAN
Director
- 3058
87.61 USD
8 months ago
Feb 21, 2024
Sell 104 K USD
Chopra Daveen
CVP, TMTT
- 1200
86.6702 USD
8 months ago
Feb 21, 2024
Sell 607 K USD
Chopra Daveen
CVP, TMTT
- 7000
86.7525 USD
9 months ago
Feb 13, 2024
Sell 1.73 M USD
Szyman Catherine M.
CVP, Critical Care
- 20000
86.46 USD
9 months ago
Feb 15, 2024
Sell 2.31 M USD
Szyman Catherine M.
CVP, Critical Care
- 27000
85.6168 USD
9 months ago
Feb 13, 2024
Sell 40.6 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 470
86.3457 USD
9 months ago
Feb 13, 2024
Sell 904 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 10530
85.8094 USD
9 months ago
Feb 12, 2024
Sell 1.06 M USD
SELLERS ROBERT W.A.
SVP, Corporate Controller
- 12210
87 USD
9 months ago
Feb 08, 2024
Sell 610 K USD
STONE HEISZ LESLIE
Director
- 7056
86.45 USD
9 months ago
Feb 05, 2024
Sell 89.6 K USD
MUSSALLEM MICHAEL A
Director
- 1000
89.61 USD
9 months ago
Feb 05, 2024
Sell 569 K USD
MUSSALLEM MICHAEL A
Director
- 6422
88.63 USD
9 months ago
Feb 05, 2024
Sell 844 K USD
MUSSALLEM MICHAEL A
Director
- 9761
86.44 USD
9 months ago
Feb 05, 2024
Sell 1.07 M USD
MUSSALLEM MICHAEL A
Director
- 12167
87.55 USD
9 months ago
Feb 01, 2024
Sell 568 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
78.29 USD
10 months ago
Jan 12, 2024
Sell 757 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 10000
75.67 USD
10 months ago
Jan 05, 2024
Sell 184 K USD
MUSSALLEM MICHAEL A
Director
- 2500
73.46 USD
10 months ago
Jan 05, 2024
Sell 1.96 M USD
MUSSALLEM MICHAEL A
Director
- 26850
72.94 USD
10 months ago
Dec 29, 2023
Sell 1.11 M USD
Ullem Scott B.
CVP, Chief Financial Officer
- 14510
76.5537 USD
11 months ago
Dec 15, 2023
Sell 548 K USD
Chopra Daveen
CVP, TMTT
- 7000
78.2463 USD
11 months ago
Dec 13, 2023
Sell 575 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 8000
71.86 USD
11 months ago
Dec 13, 2023
Sell 622 K USD
Wood Larry L
Global President TAVR & Surg
- 8658
71.86 USD
11 months ago
Dec 13, 2023
Sell 138 K USD
MUSSALLEM MICHAEL A
Director
- 1828
75.73 USD
11 months ago
Dec 13, 2023
Sell 234 K USD
MUSSALLEM MICHAEL A
Director
- 3200
73.15 USD
11 months ago
Dec 13, 2023
Sell 787 K USD
MUSSALLEM MICHAEL A
Director
- 10600
74.22 USD
11 months ago
Dec 13, 2023
Sell 1.03 M USD
MUSSALLEM MICHAEL A
Director
- 13722
75.12 USD
11 months ago
Dec 06, 2023
Sell 245 K USD
Chopra Daveen
CVP, TMTT
- 3500
70.0016 USD
1 year ago
Nov 13, 2023
Sell 6.62 K USD
Wood Larry L
Global President TAVR & Surg
- 100
66.21 USD
1 year ago
Nov 13, 2023
Sell 204 K USD
Wood Larry L
Global President TAVR & Surg
- 3158
64.6845 USD
1 year ago
Nov 13, 2023
Sell 355 K USD
Wood Larry L
Global President TAVR & Surg
- 5402
65.6359 USD
1 year ago
Nov 13, 2023
Sell 149 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 2300
64.7179 USD
1 year ago
Nov 13, 2023
Sell 243 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 3700
65.6565 USD
1 year ago
Nov 03, 2023
Sell 1.97 M USD
MUSSALLEM MICHAEL A
Director
- 29350
67.18 USD
1 year ago
Oct 31, 2023
Sell 455 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
62.6559 USD
1 year ago
Oct 13, 2023
Sell 244 K USD
Wood Larry L
Global President TAVR & Surg
- 3510
69.6109 USD
1 year ago
Oct 13, 2023
Sell 362 K USD
Wood Larry L
Global President TAVR & Surg
- 5150
70.2648 USD
1 year ago
Oct 13, 2023
Sell 139 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 2000
69.5778 USD
1 year ago
Oct 13, 2023
Sell 211 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 3000
70.2512 USD
1 year ago
Oct 10, 2023
Sell 363 K USD
Szyman Catherine M.
CVP, Critical Care
- 5000
72.68 USD
1 year ago
Oct 03, 2023
Sell 595 K USD
Chopra Daveen
CVP, TMTT
- 8500
70 USD
1 year ago
Oct 02, 2023
Sell 2.02 M USD
MUSSALLEM MICHAEL A
Director
- 29350
68.84 USD
1 year ago
Sep 29, 2023
Sell 505 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
69.542 USD
1 year ago
Sep 14, 2023
Sell 332 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 4500
73.71 USD
1 year ago
Sep 14, 2023
Sell 638 K USD
Wood Larry L
Global President TAVR & Surg
- 8660
73.6276 USD
1 year ago
Sep 08, 2023
Sell 380 K USD
Szyman Catherine M.
CVP, Critical Care
- 5000
76 USD
1 year ago
Sep 06, 2023
Sell 647 K USD
Chopra Daveen
CVP, TMTT
- 8500
76.0717 USD
1 year ago
Sep 05, 2023
Sell 2.23 M USD
MUSSALLEM MICHAEL A
Director
- 29350
75.86 USD
1 year ago
Aug 31, 2023
Sell 564 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
77.79 USD
1 year ago
Aug 29, 2023
Sell 115 K USD
Chopra Daveen
CVP, TMTT
- 1500
76.6936 USD
1 year ago
Aug 14, 2023
Sell 357 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 4500
79.3 USD
1 year ago
Aug 14, 2023
Sell 509 K USD
Wood Larry L
Global President TAVR & Surg
- 6421
79.3 USD
1 year ago
Aug 10, 2023
Sell 261 K USD
STONE HEISZ LESLIE
Director
- 3303
78.8703 USD
1 year ago
Aug 09, 2023
Sell 393 K USD
Szyman Catherine M.
CVP, Critical Care
- 5000
78.637 USD
1 year ago
Aug 07, 2023
Sell 24.2 K USD
MUSSALLEM MICHAEL A
Director
- 300
80.54 USD
1 year ago
Aug 07, 2023
Sell 2.32 M USD
MUSSALLEM MICHAEL A
Director
- 29050
79.86 USD
1 year ago
Jul 31, 2023
Sell 612 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
84.35 USD
1 year ago
Jul 14, 2023
Sell 325 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 3500
92.9358 USD
1 year ago
Jul 14, 2023
Sell 805 K USD
Wood Larry L
Global President TAVR & Surg
- 8660
92.938 USD
1 year ago
Jul 10, 2023
Sell 453 K USD
Szyman Catherine M.
CVP, Critical Care
- 5000
90.52 USD
1 year ago
Jul 05, 2023
Sell 695 K USD
MUSSALLEM MICHAEL A
Director
- 7622
91.22 USD
1 year ago
Jul 05, 2023
Sell 1.97 M USD
MUSSALLEM MICHAEL A
Director
- 21728
90.63 USD
1 year ago
Jun 30, 2023
Sell 677 K USD
Ullem Scott B.
CVP, Chief Financial Officer
- 7255
93.27 USD
1 year ago
Jun 14, 2023
Sell 314 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 3500
89.77 USD
1 year ago
Jun 14, 2023
Sell 259 K USD
Wood Larry L
Global President TAVR & Surg
- 2850
90.7117 USD
1 year ago
Jun 14, 2023
Sell 522 K USD
Wood Larry L
Global President TAVR & Surg
- 5810
89.8713 USD
1 year ago
Jun 13, 2023
Sell 429 K USD
Szyman Catherine M.
CVP, Critical Care
- 5000
85.809 USD
1 year ago
Jun 01, 2023
Sell 442 K USD
MUSSALLEM MICHAEL A
Director
- 5300
83.43 USD
1 year ago
Jun 01, 2023
Sell 459 K USD
MUSSALLEM MICHAEL A
Director
- 5396
85.08 USD
1 year ago
Jun 01, 2023
Sell 1.58 M USD
MUSSALLEM MICHAEL A
Director
- 18654
84.57 USD
1 year ago
May 24, 2023
Sell 541 K USD
Wood Larry L
Global President TAVR & Surg
- 6421
84.23 USD
1 year ago
May 10, 2023
Sell 223 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 2500
89.22 USD
1 year ago
May 10, 2023
Sell 1.48 M USD
Ullem Scott B.
CVP, Chief Financial Officer
- 16581
89.2217 USD
1 year ago
May 10, 2023
Sell 5.67 M USD
Ullem Scott B.
CVP, Chief Financial Officer
- 64119
88.361 USD
1 year ago
May 10, 2023
Sell 532 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 5984
88.94 USD
1 year ago
May 10, 2023
Sell 1.23 M USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 13891
88.29 USD
1 year ago
May 09, 2023
Sell 589 K USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 6640
88.68 USD
1 year ago
May 09, 2023
Sell 6.72 M USD
Szyman Catherine M.
CVP, Critical Care
- 75600
88.9449 USD
1 year ago
May 05, 2023
Sell 499 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 5635
88.625 USD
1 year ago
Apr 28, 2023
Sell 1.07 M USD
SELLERS ROBERT W.A.
SVP, Corporate Controller
- 12270
87.2 USD
1 year ago
Apr 14, 2023
Sell 323 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 3816
84.61 USD
1 year ago
Apr 14, 2023
Sell 1.35 M USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 16059
84.1 USD
1 year ago
Apr 06, 2023
Sell 559 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 6725
83.0931 USD
1 year ago
Apr 06, 2023
Sell 552 K USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 6640
83.0973 USD
1 year ago
Mar 15, 2023
Sell 344 K USD
Chopra Daveen
CVP, TMTT
- 4435
77.4662 USD
1 year ago
Mar 14, 2023
Sell 709 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 9175
77.32 USD
1 year ago
Mar 14, 2023
Sell 833 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 10700
77.86 USD
1 year ago
Mar 08, 2023
Sell 3.87 K USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 50
77.43 USD
1 year ago
Mar 08, 2023
Sell 507 K USD
Lemercier Jean-Luc M
CVP, EMEACLA and JAPAC
- 6590
76.9537 USD
1 year ago
Mar 08, 2023
Sell 518 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 6725
76.9603 USD
1 year ago
Feb 16, 2023
Sell 743 K USD
STONE HEISZ LESLIE
Director
- 9671
76.8216 USD
1 year ago
Feb 15, 2023
Sell 304 K USD
Chopra Daveen
CVP, TMTT
- 4000
76.01 USD
1 year ago
Feb 14, 2023
Sell 280 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 3600
77.75 USD
1 year ago
Feb 14, 2023
Sell 1.25 M USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 16275
76.83 USD
1 year ago
Feb 06, 2023
Sell 543 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 6725
80.75 USD
1 year ago
Jan 17, 2023
Sell 312 K USD
Chopra Daveen
CVP, TMTT
- 4000
78 USD
1 year ago
Jan 13, 2023
Sell 1.55 M USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 19875
78.0943 USD
1 year ago
Jan 09, 2023
Sell 521 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 6725
77.5 USD
1 year ago
Dec 15, 2022
Sell 299 K USD
Chopra Daveen
CVP, Surgical Structural Heart
- 4000
74.8 USD
1 year ago
Dec 14, 2022
Sell 23.3 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 300
77.51 USD
1 year ago
Dec 14, 2022
Sell 571 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 7420
76.93 USD
1 year ago
Dec 14, 2022
Sell 924 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 12155
76.04 USD
1 year ago
Dec 13, 2022
Sell 23.2 K USD
Wood Larry L
CVP, TAVR
- 300
77.4833 USD
1 year ago
Dec 13, 2022
Sell 534 K USD
Wood Larry L
CVP, TAVR
- 6936
76.9567 USD
1 year ago
Dec 12, 2022
Sell 500 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 6725
74.32 USD
2 years ago
Nov 15, 2022
Sell 297 K USD
Chopra Daveen
CVP, Surgical Structural Heart
- 4000
74.18 USD
2 years ago
Nov 14, 2022
Sell 15.1 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 200
75.47 USD
2 years ago
Nov 14, 2022
Sell 307 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 4100
74.86 USD
2 years ago
Nov 14, 2022
Sell 1.15 M USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 15575
73.94 USD
2 years ago
Nov 08, 2022
Sell 460 K USD
BOBO DONALD E JR
CVP,Strategy/Corp Development
- 6725
68.46 USD
2 years ago
Nov 08, 2022
Sell 496 K USD
Wood Larry L
CVP, TAVR
- 7242
68.4983 USD
2 years ago
Oct 14, 2022
Sell 51.2 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 600
85.28 USD
2 years ago
Oct 14, 2022
Sell 152 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 1800
84.64 USD
2 years ago
Oct 14, 2022
Sell 248 K USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 2978
83.38 USD
2 years ago
Oct 14, 2022
Sell 1.19 M USD
MUSSALLEM MICHAEL A
Chairman & CEO
- 14497
82.41 USD
2 years ago
Oct 14, 2022
Sell 339 K USD
Chopra Daveen
CVP, Surgical Structural Heart
- 4000
84.77 USD
2 years ago
Oct 11, 2022
Sell 595 K USD
Wood Larry L
CVP, TAVR
- 7242
82.12 USD
7. News
Investors With Losses Are Invited To Join The Schall Law Firm In A Fraud Case Against Edwards Lifesciences Corporation LOS ANGELES, CA / ACCESSWIRE / November 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024. accesswire.com - 20 hours ago
EW Equity Alert: Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Fraud Class Action Lawsuit Filed against Edwards Lifesciences Corporation RADNOR, Pa. , Nov. 16, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024. prnewswire.com - 22 hours ago
EW FRAUD ALERT: Suffer Losses on Your Edwards Lifesciences Securities? Contact BFA Law before December 13 Securities Fraud Class Action Deadline (NYSE:EW) Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024 legal deadline. globenewswire.com - 1 day ago
EW INVESTOR ALERT: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit SAN DIEGO, CA / ACCESSWIRE / November 15, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE:EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. accesswire.com - 1 day ago
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit LOS ANGELES , Nov. 15, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW). Class Period: February 6, 2024 – July 24, 2024 Lead Plaintiff Deadline: December 13, 2024 If you wish to serve as lead plaintiff of the Edwards Lifesciences lawsuit, you can submit your contact information at www.glancylaw.com/cases/edwards-lifesciences-corporation/. prnewswire.com - 1 day ago
Class Action Filed Against Edwards Lifesciences Corporation (EW) Seeking Recovery for Investors – Contact Levi & Korsinsky NEW YORK, NY / ACCESSWIRE / November 15, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112173&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 1 day ago
Shareholders That Lost Money on Edwards Lifesciences Corporation (EW) Should Contact Levi & Korsinsky About Pending Class Action - EW NEW YORK, NY / ACCESSWIRE / November 15, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112161&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 1 day ago
Edwards Lifesciences Corporation Is Being Sued For Violating Securities Laws And The Schall Law Firm Encourages Affected Shareholders To Take Part LOS ANGELES, CA / ACCESSWIRE / November 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024. accesswire.com - 1 day ago
December 13, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - EW NEW YORK, NY / ACCESSWIRE / November 15, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112145&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 1 day ago
Edwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion Of Market Capitalization – Hagens Berman SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. globenewswire.com - 1 day ago
Contact Levi & Korsinsky by December 13, 2024 Deadline to Join Class Action Against Edwards Lifesciences Corporation(EW) NEW YORK, NY / ACCESSWIRE / November 15, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112141&wire=1 or contact Joseph E. Levi, Esq. accesswire.com - 1 day ago
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options globenewswire.com - 1 day ago
8. Profile Summary

Edwards Lifesciences Corporation EW

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 40 B
Dividend Yield 0.00%
Description Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Contact One Edwards Way, Irvine, CA, 92614 https://www.edwards.com
IPO Date March 27, 2000
Employees 19800
Officers Mr. Donald E. Bobo Jr. Corporate Vice President of Strategy & Corporate Development Mr. Mark Wilterding Vice President of Investor Relations Dr. Todd J. Brinton FACC, M.D. Corporate Vice President of Advanced Technology & Chief Scientific Officer Mr. Gary I. Sorsher Senior Vice President of Quality & Regulatory Compliance Mr. Andrew M. Dahl Principal Accounting Officer, Senior Vice President & Corporate Controller Mr. Scott B. Ullem Corporate Vice President & Chief Financial Officer Mr. Dirksen J. Lehman Corporate Vice President of Public Affairs Ms. Christine Z. McCauley Corporate Vice President of Human Resources Mr. Larry L. Wood Corporate Vice President and Group President of TAVR & Surgical Structural Heart Mr. Bernard J. Zovighian Chief Executive Officer & Director